Fundz

CILA Therapeutics has been awarded a competitive NCATS grant to advance its CIL-Key™ platform for inhaled RNA delivery, enhancing treatment potential for pulmonary diseases.

PRIVATEAug 15, 2025

Round Type

Grant

BostonBiotechnologyHealth CareTherapeutics

Description

CILA Therapeutics has received a grant from the National Center for Advancing Translational Sciences to advance its CIL-Key™ platform. This technology significantly improves the delivery of inhaled RNA-loaded lipid nanoparticles into lung cells. The milestone validates the company's scientific approach and vision for tackling pulmonary challenges. CILA aims to develop breakthrough RNA therapeutics and vaccines through this platform.

Who else raised in Therapeutics and Biotechnology around the same time

Companies in the same sectors as CILA Therapeutics that raised within 45 days of this round, from Fundz verified event records.

  • Aarvik Therapeutics raised an undisclosed amount (Seed) on September 29, 2025.
  • Corner Therapeutics raised $17M on September 26, 2025.
  • MAIA Biotechnology raised $2.3M (Grant) on September 24, 2025.
  • Santhera Pharmaceuticals raised $21M (Funding Round) on September 23, 2025.
  • AusperBio raised $63M (Series B) on September 22, 2025.
  • Nuclide Therapeutics raised $6.7M (Seed) on September 22, 2025.

Who to call at CILA Therapeutics, and when

A new round usually means CILA Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day CILA Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at CILA Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at CILA Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

CILA Therapeutics

Location

Boston, Massachusetts, United States

About

CILA Therapeutics is a biotechnology company focused on improving lung health through transformative, scalable, accessible therapies and technologies that easily integrate into patients’ daily lives. Its vision is to empower people with pulmonary diseases to breathe easily and live fully. CILA’s pipeline includes first-in-class inhaled therapeutics and CIL-Key™, a proprietary platform to enhance delivery of RNA-based therapeutics and vaccines targeting a wide spectrum of pulmonary diseases.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment CILA Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for CILA Therapeutics's next move

See what Strategic adds

CILA Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.